Insights into Herpes Labialis Treatment Market: Emerging Strategies and Market Outlook (2023 to 2033)

The global demand for herpes labialis treatment t is likely to register a CAGR of 4.7% between 2023 and 2033. FMI estimates that the global herpes labialis treatment market size could reach USD 1.79 billion by 2033, up from USD 1.13 billion in 2023. The high prevalence of herpes labialis simplex virus infections, especially oral herpes, is responsible for the expansion.

Herpes labialis, commonly termed oral herpes, is a mouth infection that results in the development of minute and uncomfortable blisters on the lips, gums, or neck. The herpes simplex virus, which is common and highly infectious and infects plenty of people in North America by the age of 20, is the source of these blisters. The infection is frequently brought on by Herpes Simplex Virus type 1 (HSV-1), although it can also be brought on by Herpes Simplex Virus type 2 (HSV-2).

Since herpes labialis infections are becoming more common globally, the herpes labialis treatment market has seen a surge in growth lately. The HSV-1 virus, which is the main cause of herpes labialis, is suspected of impacting 3.7 billion individuals under the age of 50. Based on a report from the World Health Organization in 2020.

Herpes labialis should always be diagnosed and treated as soon as possible to control the symptoms and stop the infection from spreading. More people are seeking immediate medical attention for herpes labialis. As a result of increased awareness of the significance of early diagnosis and treatment, leading to market expansion.

Herpes labialis is commonly treated with topical antiviral creams like acyclovir, penciclovir, and docosanol. Given their ease of use and comfort, these creams offer targeted therapy and are appreciated by patients. Topical antiviral creams are increasingly being used as the first line of therapy for herpes labialis, and this trend is anticipated to continue boosting the sales of these products.

Herpes labialis symptoms are also increasingly managed using over-the-counter (OTC) medicines such as lotions, ointments, and lip balms. These are well-liked by customers since they are easily available and can be purchased without a prescription. The demand for these products is anticipated to be driven by the tendency of self-medication and the increased availability of OTC medications in various retail channels.

Herpes labialis is also being treated with combination therapy, which includes antiviral drugs with topical creams or other treatment modalities, such as corticosteroids. There is potential for the development of groundbreaking combination treatments that could lead to better results in terms of symptom alleviation, a decrease in the frequency of outbreaks, and faster healing.

To provide affordable pharmaceuticals for the treatment of viral infections, several manufacturers are emphasizing the approval and introduction of generic treatments in developing countries. Hence, the increasing advancements in the prevention of herpes labialis infection are likely to present producers of herpes labialis medications with promising opportunities. For instance, Perrigo stated in February 2019 that a generic version of Bausch Health's Zovirax (acyclovir) cream has received FDA clearance and an AB rating.

Attributes Details
Herpes Labialis Treatment Market Value (2023) USD 1.13 billion
Herpes Labialis Treatment Market Expected Value (2033) USD 1.79 billion
Herpes Labialis Treatment Market Projected CAGR (2023 to 2033) 4.7%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Herpes Labialis Treatment Market Outlook Compared to 2023 to 2033 Forecast

The herpes labialis treatment market expanded at a CAGR of 4.2% between 2018 and 2022.

A few of the primary drivers behind the market growth:

  • The growing incidence of HSV infections
  • The seismic shift in governments towards precautionary treatment options for infectious diseases
  • Increased investments in research and development activities by both governmental authorities and key market participants

Depending on the individual, the frequency and intensity of herpes labialis outbreaks could vary. Around 20–40% of people with recurrent herpes labialis could suffer outbreaks at least once each year, based on certain research. Whereas others could experience less frequent recurrences. The United States Food and Drug Administration announced the updated recommendations for the development of antiviral medications, especially for the treatment of recurrent herpes labialis in November 2017. These recommendations were developed to aid in the investigation of safety testing, which is crucial for the approval of any antiviral medication.

  • Short Term (2023 to 2026): During this timeframe, demand for antiviral drugs like acyclovir, valacyclovir, and famciclovir that are used to treat herpes labialis is anticipated to increase. With growing understanding and improved access to healthcare, these drugs are frequently given for controlling infections and minimizing the duration and severity of symptoms. Short-term growth is also projected for topical creams containing antiviral ingredients such as docosanol and penciclovir. Patients frequently choose these creams because they can help lessen discomfort and speed up recovery.
  • Medium Term (2026 to 2029): The discovery of radical treatments for herpes labialis could provide prospects for mid-term growth. This could involve brand-new antiviral medications with enhanced effectiveness and safety profiles. As well as innovative therapeutic approaches like gene therapy or immunotherapies that specifically target the herpes simplex virus (HSV). The market expansion could be further influenced by telemedicine and digital health solutions. Patients in underdeveloped regions could have easier access to treatment alternatives owing to remote medical consultations, telemedicine, and online pharmacy services. This is likely to raise the demand for herpes labialis treatment.
  • Long Term (2029 to 2033): Developing and approving efficient herpes labialis vaccines could bring about sizable long-term business potential. Although there is presently no HSV vaccine on the market, future research on HSV vaccines has the potential to completely change how herpes labialis is treated and prevented. Customized herpes labialis treatment regimens based on a patient's genetic profile, immunological response, and other unique variables. This could be possible owing to developments in personalized medicine, such as genetic testing and precision medicine methods.

FMI expects the herpes labialis treatment market may expand at a CAGR of 4.7% during the forecast period.

Exploring the Regional Patterns of the Herpes Labialis Treatment Market: An In-depth Examination at the Country Level

Is the Herpes Labialis Treatment in the United States Progressing with Promising Innovations?

The dominance of North America over other regions of the global market is anticipated to increase with the presence of numerous notable companies in the region. In 2022, the United States accounted for around 92% share of the North America herpes labialis treatment market. This can be ascribed to increased use of premium herpes medications, rising healthcare expenditure, an increase in the introduction of generic medications, and supportive reimbursement policies.

By establishing criteria for the safety and effectiveness of therapies, the United States Food and Drug Administration plays a critical role in regulating the herpes labialis treatment industry. In recent years, the United States FDA has authorized many novel medications and herpes labialis therapy alternatives. For instance, the FDA authorized the topical cream Xerese (acyclovir and hydrocortisone) in 2020 for the treatment of recurrent herpes labialis in immunocompetent individuals. With receiving this clearance, patients with herpes labialis in the United States now have more treatment alternatives.

The United States herpes labialis treatment market is also being driven by variables including rising disease prevalence, an aging and immunocompromised population, and an increase in serological testing for herpes infection. For instance, the CDC estimates that in the United States, 11.9% of individuals between the ages of 11 and 49 are infected. The commencement of an observational clinical study for recurrent HSV-2 infection with 200 patients for the company's product RVx-001-PSS was announced by Rational Vaccines Inc. in August 2022.

Market participants in the United States have joined forces and made acquisitions to diversify their product portfolios and increase their market share. For instance, TESARO Inc., a biopharmaceutical business with a pipeline of experimental cancer therapies, including a possible therapy for herpes labialis, was obtained by GlaxoSmithKline (GSK) in 2020. These partnerships and purchases may help the market generate new and better therapeutic solutions.

What Innovations are Altering the Landscape of Herpes Labialis Treatment in Germany?

Germany held about 22% share of the Western Europe herpes labialis treatment market in the year 2022. The Germany herpes labialis treatment market is experiencing growth since there is a growing patient population with HSV infections and improved facilities for healthcare. According to the Robert Koch Institute, the estimated prevalence of HSV-1 infection, which is a common cause of herpes labialis, in Germany is around 60-90% of the population.

The utilization and approval of drugs for herpes labialis are governed by Germany regulatory agencies. Such as the Federal Institute for Drugs and Medical Devices and the Paul-Ehrlich Institute. These guidelines make sure that the treatment alternatives on the market are both safe and efficient, as well as meeting the required levels of quality, which in turn increases public confidence in the market.

Recent developments in the production of antiviral drugs and topical creams for the treatment of herpes labialis have occurred in Germany. Also, there has been an increase in demand for herbal and natural treatments in Germany for the treatment of herpes labialis. Players in the market are developing products with natural components renowned for their antiviral characteristics, such as tea tree oil and lemon balm.

Are Herpes Labialis Patients in China Finding Hope in New Therapies?

China accounted for 44.3% share 2022 of the Asia Pacific herpes labialis treatment market. Herpes labialis is becoming more common in China, which has increased the demand for effective treatment alternatives and fueled market expansion. Given government investments in enhancing healthcare infrastructure and facilities, China has seen a growth in healthcare expenditure. The market has grown as a consequence of easier access to healthcare services, especially those for herpes labialis diagnosis and treatment.

China herpes labialis treatment market is expected to expand at a CAGR of 6.1% from 2023 to 2033. Herpes labialis is one of several illnesses that are commonly treated in China with Traditional Chinese medicine (TCM). Herbal medications, acupuncture, and other TCM-based treatments have grown increasingly well-liked in China because many believe they work better and have fewer adverse effects than conventional therapies. This has increased demand in China for TCM-based herpes labialis therapies.

The herpes labialis treatment industry in China is actively occupied by numerous both local and international pharmaceutical companies, fostering competition and innovation. For instance, the National Medical Products Administration (NMPA) granted permission to Livzon Pharmaceutical Group Inc. In 2019 for their acyclovir cream, which is used to treat herpes labialis. Livzon is a well-known pharmaceutical business in China.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Exploring the Herpes Labialis Treatment Market: An In-depth Segment Analysis

Why is the Demand for Acyclovir Drugs for Treating Herpes Labialis Increasing?

The commonly prescribed medication for treating cold sores is acyclovir. Thus, sales of acyclovir are projected to expand at a CAGR of 5.1% over the forecast period. Acyclovir functions by preventing the HSV from replicating, lessening the severity and length of outbreaks, and easing symptoms like pain and suffering related to cold sores. Patients can easily and conveniently get acyclovir since it comes in a variety of forms, including topical creams, ointments, and oral pills.

Healthcare professionals and individuals are becoming more knowledgeable about herpes labialis. As a result, the advantages of acyclovir in treating the illness are becoming more widely acknowledged. Acyclovir is now being given for herpes labialis more frequently as a result, which has raised the demand for the medication in the market.

Why do Hospitals Contribute to Maximum Market Share by Distribution Channels?

The hospitals segment held a 35.4% market share in terms of distribution in 2022, showing strong sales of herpes labialis treatment medications through hospital pharmacies. The expansion could additionally be attributed to the availability of comprehensive treatment and expert medical personnel in hospitals. With expertise in diagnosis and treatment, hospitals offer a wide range of options including antiviral medications, pain management, and supportive therapies.

Hospitals keep up with the recent developments in the industry because they have cutting-edge diagnostic equipment and facilities. Given their reliability, hospitals are frequently preferred by patients for herpes labialis therapy. The inclusion of hospitals in insurance coverage plans and their referral network from other healthcare providers also help to increase their market share.

Herpes Labialis Treatment Market: Analyzing Key Players, Strategies, and Market Share in the Global Landscape

Company GlaxoSmithKline
Development Shingrix, a recombinant herpes zoster vaccine produced by GlaxoSmithKline, received FDA clearance in the United States in July 2021. When an adult over the age of 18 is in danger of getting herpes zoster owing to any known immunosuppressive factors, this can be utilized as a preventative measure.
Strategy GSK's strategy for Shingrix includes identifying the target market of immunosuppressed adults at risk for shingles and comprehending their requirements and preferences. It also focuses on pricing the vaccine competitively and putting in place marketing initiatives to increase awareness and encourage adoption.
Company Amneal Pharmaceuticals, LLC
Development In November 2020, for the prevention of recurrent herpes labialis (cold sores) in immunocompetent individuals who are 12 years of age and older, Amneal Pharmaceuticals, LLC officially declared that the FDA has accepted its Abbreviated New Drug Application (ANDA) for Acyclovir Cream, 5%, the substitute for Zovirax.
Strategy Amneal Pharmaceuticals, LLC aims to gain ground in the market for preventing recurrent herpes labialis. The approach focuses on offering a cost-effective substitute for the branded medicine while leveraging the existing market need for herpes labialis treatments, with a target audience of immunocompetent adults aged 12 and older.
Company Bayer AG
Development Bayer AG started the investigation for the treatment of herpes labialis in patients with a healthy immune system using the sitavig (acyclovir) buccal tablet. It also reported that it is undertaking Phase 3 clinical investigations in June 2022. By October 2023, the study is anticipated to be finished.
Strategy With a strategic focus on completing its clinical studies and securing regulatory permission for commercialization, Bayer AG appears to be actively encouraging the development of Sitavig as a potential therapy for this disease.
Company GC Biopharma Inc.
Development GC Biopharma Inc. unveiled Pojinen cream, an OTC medication, in January 2022 as a combined treatment for recurrent herpes labialis. The cream includes 10mg/g of hydrocortisone, which has anti-inflammatory qualities, and 50mg/g of acyclovir, which stops the herpes virus from multiplying. The combination of these substances aims to shorten the typical treatment period.
Strategy The goal of GC Biopharma Inc. is to reduce the duration of medication for recurrent herpes labialis by offering a combination treatment approach that tackles both viral replication and inflammation. Moreover, it distinguishes itself by a dual-action strategy, a focus on effectiveness, and comprehensive customer education.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

How can Manufacturers Expand in the Herpes Labialis Treatment Market?

Expanding in the herpes labialis treatment market can be challenging given the competitive landscape and regulatory requirements. Nonetheless, there are several strategies that market players can consider to increase their presence in the market:

  • Invest in research and development to develop innovative and effective treatments.
  • Establish market strategies, pricing, and distribution channels that are customized to the demands of potential customer categories.
  • Build resilient relationships with healthcare professionals including dermatologists, dentists, and general physicians to promote brand visibility and referrals.
  • Collaborate with experts in the field of herpes labialis to gain credibility and endorsement for products.
  • Identify and target specific segments of the market based on age groups, demographics, or geographical regions.
  • Keep up with regulatory standards and make sure that herpes labialis therapies are in line with regulations at the national and international levels.
  • Monitor and adapt to market trends, including changes in consumer preferences, competitive landscape, and technological advancements.
  • Offer first-rate customer service, including patient support programs to foster client loyalty and trust.

Key Companies

  • Novartis AG
  • Valeant Pharmaceuticals International Inc. (Bausch Health)
  • Teva Pharmaceuticals Industries Ltd.
  • Bayer AG
  • Sun Pharmaceuticals
  • Abbott Laboratories
  • Amneal Pharmaceuticals, LLC
  • Mylan N.V.
  • Pfizer Inc.
  • GlaxoSmithKline PLC.
  • Dr. Reddy’s Laboratories
  • GC Biopharma Inc.

Herpes Labialis Treatment Industry Segmentation

By Drug Type:

  • Acyclovir
  • Valacyclovir
  • Penciclovir
  • Famciclovir
  • Docosanol

By Route of Administration:

  • Oral
  • Topical
  • Combination

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific excluding Japan
  • Japan
  • The Middle East & Africa

Frequently Asked Questions

How Big is the Herpes Labialis Treatment Market? 

The market is valued at USD 1.1 billion in 2023. 

Who are the Key Performers of the Market? 

Novartis AG, and Teva Pharmaceuticals Industries Ltd. are key market players. 

What is the CAGR from 2023 to 2033? 

The market’s CAGR from 2023 to 2033 will be 4.7%. 

What Players will Sustain Success in the Market? 

Rising use of systemic antiviral drugs for severe and recurrent cases.

Which is the Key Segment by Drug Type in the Market? 

Acyclovir segment is likely to remain preferred through 2033. 

Table of Content
  • 1. Executive Summary | Herpes Labialis Treatment Market
  • 2. Market Overview
  • 3. Market Background
  • 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
  • 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
    • 5.1. Acyclovir
    • 5.2. Valacyclovir
    • 5.3. Penciclovir
    • 5.4. Famciclovir
    • 5.5. Docosanol
  • 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
    • 6.1. Oral
    • 6.2. Topical
    • 6.3. Combination
  • 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    • 7.1. Hospital Pharmacies
    • 7.2. Retail Pharmacies
    • 7.3. Online Pharmacies
  • 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    • 8.1. North America
    • 8.2. Latin America
    • 8.3. Europe
    • 8.4. South Asia
    • 8.5. East Asia
    • 8.6. Oceania
    • 8.7. MEA
  • 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 16. Key Countries Market Analysis
  • 17. Market Structure Analysis
  • 18. Competition Analysis
    • 18.1. Novartis AG
    • 18.2. Valeant Pharmaceuticals International Inc.
    • 18.3. Teva Pharmaceuticals Industries Ltd.
    • 18.4. Sun Pharmaceuticals
    • 18.5. Abbott Laboratories
    • 18.6. Mylan N.V.
    • 18.7. Pfizer Inc.
    • 18.8. GlaxoSmithKline PLC
    • 18.9. Dr. Reddy’s Laboratories
    • 18.10. Merck & Co., Inc.
  • 19. Assumptions & Acronyms Used
  • 20. Research Methodology
Recommendations

Healthcare

Salivary Gland Infection Treatment Market

February 2023

REP-GB-16730

295 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Herpes Labialis Treatment Market

Schedule a Call